Medicus Pharma Ltd MDCX 深 沪
等待开盘 03-26 09:30:00 美东时间
0.4939
+0.005
+1.00%
华盛通- 最 高0.4939
- 今 开0.48
- 成交量 120.67万股
- 最 低 0.4627
- 昨 收 0.489
- 总市值 1261.91万
- 52周最高 8.94
- 市盈率 静 --
- 换手率 4.72%
- 52周最低 0.37
- 委 比 -98.18%
- 总股本 2555.00万
- 历史最高 8.94
- 量 比 0.96
- 振 幅 6.38%
- 历史最低 0.37
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.15) by 442.48 percent.
今天 04:40
Medicus Pharma To Update Review Of SkinJect SKNJCT-003 Phase 2 Clinical Trial Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.PHILADELPHIA, PA / ACCESS Newswire / March 18,
03-18 19:35
Medicus Pharma executives to join Brookline Capital Markets fireside chat on SkinJect Phase 2 results showing 73% clearance
Medicus Pharma executives to join Brookline Capital Markets fireside chat on SkinJect Phase 2 results showing 73% clearance Medicus will participate in a live fireside chat on March 19, 2026, hosted by Brookline Capital Markets analyst Kumaraguru Raja. Executive Chairman and CEO Raza Bokhari is sche
03-18 19:30
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
Medicus Pharma reported 73% clinical clearance and 40% histological clearance in the 200-µg cohort of their Phase 2 SKNJCT-003 study evaluating SkinJect® microneedle delivery for basal cell carcinoma. The study highlights the efficacy of the 200-µg dose and suggests a non-surgical treatment option, potentially reducing the need for Mohs surgery. The findings support regulatory discussions and strategic partnerships, with plans to optimize treatme...
03-09 11:30
Medicus Pharma Stock Swings After Skin Cancer Treatment Results
Medicus Pharma stock surged then slipped after the Phase 2 trial showed a 73% clearance rate for its skin cancer treatment.
03-05 22:13
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednes...
03-04 20:05
Medicus Pharma to Join Annual Roth Conference in Dana Point
Medicus Pharma to Join Annual Roth Conference in Dana Point Medicus Pharma Ltd. (Nasdaq: MDCX) will participate in the 38th Annual Roth Conference, held March 22-24, 2026, in Dana Point, California. Executive Chairman and CEO Dr. Raza Bokhari is scheduled to join a Fireside Chat on Tuesday, March 24
03-03 20:30
Medicus Pharma To Participate in the 38th Annual Roth Conference
Medicus Pharma Ltd. will participate in the 38th Annual Roth Conference on March 22-24, 2026, in Dana Point, California. Dr. Raza Bokhari, the Company's Executive Chairman & CEO, will discuss SkinJect's potential for treating Gorlin Syndrome, an autosomal dominant rare disease, and highlight Medicus's AI-enabled drug development strategy and partnering readiness. The Fireside Chat will be available via webcast and Dr. Bokhari will meet with inves...
03-03 12:30
Medicus Pharma Receives FDA's 'Study May Proceed' Clearance To Start Phase 2B Dose-Optimization Trial Of Teverelix To Treat Advanced Prostate Cancer In Men
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
02-10 20:35
